State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in Cullinan Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 2,604,105 shares of Cullinan Therapeutics Inc. common stock.
  • Percent of class: The reported position represents 4% of the class, according to the filing.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 2,476,651 shares.
  • Shared dispositive power: The filing reports shared power to dispose or direct the disposition of 2,604,105 shares.
  • Sole voting and dispositive power: Both sole voting power and sole dispositive power are listed as 0 shares.
  • Triggering subsidiaries: The filing identifies five investment adviser subsidiaries as the entities through which the position was acquired, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, among others.

State Street's Schedule 13G Filing for Cullinan Therapeutics Common Stock

State Street Corporation, a holding company organized in Massachusetts, filed a Schedule 13G disclosing its beneficial ownership of common stock in Cullinan Therapeutics Inc. (NASDAQ:CGEM). The event date that triggered the filing was September 30, 2026, and the statement was signed on November 9, 2026 by Alok Maheshwary, Senior Vice President. State Street's principal business office is listed as One Congress Street, Suite 1, Boston, MA 02114.

According to the filing, State Street's aggregate beneficial ownership stands at 2,604,105 shares, equal to 4% of the class. The company reports no sole voting or sole dispositive power over any of those shares. Shared voting power covers 2,476,651 shares, while shared dispositive power extends to the full 2,604,105 shares. The filing classifies State Street as a parent holding company (type "HC") under Item 12.

The filing identifies five subsidiaries as the investment advisers (designated "IA") through which the reported securities were acquired: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing certifies, in State Street's own words, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Item 5 notes that the position represents ownership of 5 percent or less of the class. Cullinan Therapeutics is headquartered at 1 Main Street, Suite 520, Cambridge, Massachusetts 02142.

What Was Disclosed

State Street Corporation disclosed a 4% beneficial ownership position in Cullinan Therapeutics Inc. common stock totaling 2,604,105 shares, held through five investment adviser subsidiaries, with the position reported as of September 30, 2026.